Vanadium Salts as Insulin Substitutes: Mechanisms of Action, a Scientific and Therapeutic Tool in Diabetes Mellitus Research

References

• Bentley C., Kahn R. C. Insulin action and the insulin signaling network. Endocr.Rev. 1995; 16: 117–142
   Google Scholar
• McCall A. L. Perspectives in diabetes: the impact of diabetes on the CNS. Diabetes 1992; 41: 557–570
   PubMed Web of Science ®Google Scholar
• Rotter J. L., Vadhemin C. M., Rimonin D. L. Genetics of diabetes. Diabetes Mellitus: Theory and Practice, H. Rifkin, D. Porte, Jr. Elsevier, New York 1990; 378–413
   Google Scholar
• DeFronzo R. The triumvirate: β-Cell muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667–685
   PubMed Web of Science ®Google Scholar
• Williams G. Management of noninsulin-dependent diabetes mellitus. Lancet 1994; 343: 95–100
   PubMed Web of Science ®Google Scholar
• Nolan J. J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 1994; 331: 1188–1193
   PubMed Web of Science ®Google Scholar
• Shechter Y. Perspectives in diabetes, insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 1990; 39: 1–5
   PubMed Web of Science ®Google Scholar
• Shechter Y., Shisheva A. Vanadium salts and the future treatment of diabetes. Endeavour 1993; 17: 27–31
   PubMed Web of Science ®Google Scholar
• Brichard M. S., Henquin J. C. The role of vanadium in the management of diabetes. Trends Pharmacol. Sci. 1995; 16: 265–270
   PubMed Web of Science ®Google Scholar
• Smith M. J., Kim D., Horenstein B., Nakanishi K., Kustin K. Unraveling the chemistry of tunichrome. Acc. Chem. Res. 1991; 24: 117–124
   Google Scholar
• Shaver A., Ng B. J., Hall D. A., Posner B. I. The chemistry of peroxo vanadium compounds relevant to insulin mimesis. Mol. Cell. Biochem. 1995; 153: 5–15
   PubMed Web of Science ®Google Scholar
• Macara I. G. Vanadium: an element in search of a role. Trends Biochem. Set 1980; 5: 92–94
   Web of Science ®Google Scholar
• Ramasarma T., Crane F. L. Does vanadium play a role in Cellular regulation. Curr. Top. Cell. Regul. 1981; 20: 247–301
   PubMedGoogle Scholar
• Tolman E. L., Barris E., Burns M., Pansini A., Partridge R. Effect of vanadium on glucose metabolism. in vitro. Life Sci. 1979; 25: 1159–1164
   PubMed Web of Science ®Google Scholar
• Shechter Y., Karlish S. J. D. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl(IV) ions. Nature (London) 1980; 284: 556–558
   PubMed Web of Science ®Google Scholar
• Dubyak G. R., Kleinzeller A. D. The insulin mimetic effects of vanadate in isolated rat adipocytes. J. Biol. Chem. 1980; 255: 5306–5312
   PubMed Web of Science ®Google Scholar
• Heyliger E.C., Tahiliani G. A., McNeill J. H. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 1985; 227: 1474–1477
   PubMed Web of Science ®Google Scholar
• Hummel K. P., Dickie M. M., Coleman D. L. Diabetes, a new mutation in the mouse. Science 1966; 153: 1127–1128
   PubMed Web of Science ®Google Scholar
• Roesler W. J., Khandelwal R. L. Age related changes in hepatic glycogen metabolism in the genetically diabetic (db/db) mouse. Diabetes 1985; 34: 395–402
   Google Scholar
• Meyerovitch I., Farfel Z., Sack J., Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J. Biol. Chem. 1987; 262: 6658–6662
   PubMed Web of Science ®Google Scholar
• Brichard S. M., Okitolonda W., Henquin J. C. Long-term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 1988; 123: 2048–2053
   PubMed Web of Science ®Google Scholar
• Gil J., Miralpeix M., Carreras J., Bartrons R. Insulin-like effects of vanadate on glucokinase activity and fructose 2,-6-bisphosphate levels in the liver of diabetic rats. J. Biol. Chem. 1988; 263: 1868–1871
   PubMed Web of Science ®Google Scholar
• Blondel O., Bailbe D., Portha B. In vivo insulin-resistance in streptozotocin-diabetic rats, evidence of reversal following oral vanadate treatment. Diabetologia 1989; 32: 185–190
   PubMed Web of Science ®Google Scholar
• Bendayan M., Gingras D. Effect of vanadate administration on blood glucose and insulin level as well on the exocrine pancreatic function in streptozotocin-diabetic rats. Diabetologia 1989; 32: 561–567
   PubMed Web of Science ®Google Scholar
• Ramanadham S., Mongold J. J., Brownsey R. W., Cors G. H., McNeill J. H. Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am. J. Physiol. 1989; 257: H904–H911
   PubMed Web of Science ®Google Scholar
• Pederson R. A., Ramanadham S., Buchan A. M. J., McNeill J. H. Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes 1989; 38: 1390–1395
   PubMed Web of Science ®Google Scholar
• Sekar N., Kanthasamy A., William S., Subramanian S., Govindasamy S. Insulinic actions of vanadate in diabetic rats. Pharmacol. Res. 1990; 22: 207–217
   PubMed Web of Science ®Google Scholar
• Venkatesan N., Avidan A., Davidson M. B. Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity. Diabetes 1991; 40: 492–498
   PubMed Web of Science ®Google Scholar
• Brichard S. M., Desbuquois B., Girard J. Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: effects on glycolytic and gluconeogenic enzymes, and on glucose transport GLUT2. Mol. Cell. Endocrinol. 1993; 91: 91–97
   PubMed Web of Science ®Google Scholar
• Maneemegalai S., Sekar N., Govindasamy S. Insulin-like effect of sodium orthovanadate on urea-cycle enzymes in streptozotocin diabetic rats. J.Clin. Biochem. Nutr. 1994; 16: 187–192
   Google Scholar
• Becker D. J., Ongemba L. N., Henquin J. C. Comparison of the effects of various vanadium salts on glucose homeostasis in streptozotocin-diabetic rats. Eur. J. Pharmacol. 1994; 260: 169–175
   PubMed Web of Science ®Google Scholar
• Cam M.C., Faun J., McNeill J. H. Concentration-dependent glucose lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats. Metabolism 1995; 44: 332–339
   PubMed Web of Science ®Google Scholar
• Okumura N., Shimazu T. Vanadate stimulates D-glucose transport in sar-colemmal vesicels from rat skeletal muscles. J. Biochem. 1992; 112: 107–111
   Google Scholar
• Meyerovitch J., Shechter Y., Amir S. Vanadate stimulates in vivo glucose uptake in brain and arrests food intake and body weight gain in rats. Physiol. Behav. 1989; 45: 1113–1116
   Google Scholar
• Cam M.C., Cros G. H., Serrano J. J., Lazaro R., McNeill J. H. In vivo antidiabetic actions of naglivan, an organic vanadyl compound in STZ-induced diabetes. Diabetes Res. Clin. Pract. 1993; 20: 111–121
   PubMed Web of Science ®Google Scholar
• Yuen V. G., Orvig C., McNeill J. H. Glucose-lowering effects of a new organic vanadium-complex, bis(maltolato) oxovanadium(IV). Can. J. Physiol. Pharmacol. 1992; 71: 263–269
   Google Scholar
• Valera A., Rodriguez-Gil J. E., Bosch F. Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats. J. Clin. Invest. 1993; 92: 4–11
   PubMed Web of Science ®Google Scholar
• Rossetti L., Laughlin M. R. Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J. Clin. Invest. 1989; 84: 892–899
   PubMedGoogle Scholar
• Meyerovitch J., Becker J. M., Kahn C. R. Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. J. Clin. Invest. 1989; 84: 976–983
   PubMed Web of Science ®Google Scholar
• Begum N., Sussman K. E., Draznin B. Differential effects of diabetes on adipocyte and liver phosphotyrosine and phosphoserine phosphatase activities. Diabetes 1991; 40: 1620–1629
   PubMedGoogle Scholar
• Cros H. G., Cam M. C., Serrano J. J., Ribes G., McNeill J. H. Long-term antidiabetic activity of vanadyl after treatment withdrawal: restoration of insulin secretion. Mol. Cell. Biochem. 1995; 153: 191–195
   Google Scholar
• Al-Bayati M. A., Giri S. N., Raabe O. G., Rosenblatt L. S., Shifrine M. Time- and dose-response study of the effects of vanadate on rats: morphological and biochemical changes in organs. J. Environ. Pathol. Toxicol. Oncol. 1989; 9: 435–455
   PubMedGoogle Scholar
• Sekar N., Govindasamy S. Effects of vanadate on plasma lipoprotein profiles in experimental diabetic rats. Biochem. Int. 1991; 23: 935–940
   Google Scholar
• Sekar N., William S., Balasubramaniyam N., Kamarajan P., Govindasamy S. Optimization of sodium orthovanadate to treat streptozotocin-induced diabetic rats. J. Biosci. 1990; 15: 67–75
   Google Scholar
• Brichard S. M., Ongemba L. N., Girard J., Henquin J. C. Tissue-specific correction of lipogenic enzyme gene expression in diabetic rats given vanadate. Diabetologia 1994; 37: 1065–1072
   PubMed Web of Science ®Google Scholar
• Pugazhenthi S., Khandelwal R. L., Angel J. F. Insulin-like effect of vanadate on malic enzyme and glucoses-phosphate dehydrogenase activities in streptozotocin-induced diabetic rat liver. Biochim. Biophys. Acta 1991; 1083: 310–312
   PubMed Web of Science ®Google Scholar
• Brichard S. M., Pottier A. M., Henquin J. C. Long-term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology 1989; 125: 2728–2732
   Google Scholar
• Brichard S. M., Bailey C. J., Henquin J. C. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 1990; 39: 1326–1332
   Google Scholar
• Meyerovitch J., Rothenberg P., Shechter Y., Bonner-Weir S., Kahn C. R. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1991; 87: 1286–1294
   PubMed Web of Science ®Google Scholar
• Pugazhenthi S., Angel J. F., Khandelwal R. L. Long-term effects of vanadate on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. Metabolism 1991; 40: 941–946
   PubMed Web of Science ®Google Scholar
• Brichard S. M., Ongemba L. N., Henquin J. C. Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia 1992; 35: 522–527
   Google Scholar
• Jacobs S., Cuatrecasas P. Insulin-receptor structure and function. Endocrinol. Rev. 1981; 2: 251–263
   PubMed Web of Science ®Google Scholar
• Brunetti A., Goldfine I. D. Insulin-receptor gene expression and insulin resistance. J. Endocrinol. Invest. 1995; 18: 398–405
   Google Scholar
• Brichard S. M., Assimacopoulos-Jeannet F., Jeanrenaud B. Vanadate treatment markedly increases glucose utilization in muscle of insulin resistant fa/ fa rats without modifying glucose-transporter expression. Endocrinology 1992; 131: 311–317
   Google Scholar
• Pugazhenthi S., Tanha F., Dahl B., Khandelwal R. L. Decrease in protein tyrosine phosphatase activities in vana-date-treated obese Zucker (fa/fa) rat liver. Mol. Cell. Biochem. 1995; 153: 125–129
   Google Scholar
• Pugazhenthi S., Hussain A., Yu B., Brownsey W. R., Angel J. F., Khandelwal R. L. Vanadate induces normolipidemia and a reduction in the levels of hepatic lipogenic enzymes in obese Zucker rats. Mol Cell. Biochem. 1995; 153: 211–215
   Google Scholar
• King M. J., Pugazhenthi S., Khandelwal R. L., Sharma R. K. Membrane associated N -myristoyltransferase activity is reduced in obese (fa/fa) Zucker rat liver. Biochem. Biophys. Res. Commun. 1993; 196: 665–670
   Google Scholar
• Khandelwal R. L., Pugazhenthi S. In vivo effects of vandate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals. Mol. Cell. Biochem. 1995; 153: 87–94
   PubMed Web of Science ®Google Scholar
• Ferber S., Meyerovitch J., Kriauciunas K. M., Kahn C. R. Vanadate normalizes hyperglycemia and phosphoenolpyruvate carboxykinase mRNA levels in ob/ob mice. Metabolism 1994; 43: 1346–1354
   Google Scholar
• McNeill J. H., Yuen V. G., Dai S., Orvig C. Increased potency of vanadium using organic ligands. Mol. Cell. Biochem. 1995; 153: 175–180
   PubMed Web of Science ®Google Scholar
• Yuen V. G., Orvig C, Thompson K. H., McNeill J. H. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rat following chronic oral administration of bis(maltolato)oxo-vanadium(IV). Can. J. Phys. Pharmacol. 1993; 71: 270–276
   Google Scholar
• Sakurai H., Fujii K., Watanabe H., Tamura H. Orally active and long-term acting insulin-mimetic vanadyl complex: bis(picolinato)oxovanadium(IV). Biochem. Biophys. Res. Commun. 1995; 214: 1095–1101
   PubMed Web of Science ®Google Scholar
• Yale J-F., Lachance D., Bevan A. P., Vigeant C, Shaver A., Posner B. I. Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats. Diabetes 1995; 44: 1274–1279
   PubMed Web of Science ®Google Scholar
• Shisheva A., Ikonomov O., Shechter Y. The protein tyrosine phosphatase inhibitor, pervanadate, is a powerful an-tidiabetic agent in streptozotocin-treated diabetic rats. Endocrinology 1994; 134: 507–510
   Google Scholar
• Simons T. J. B. Vanadate — a new tool for biologists. Nature 1979; 281: 337–388, (London)
   PubMed Web of Science ®Google Scholar
• Crans D.C., Tahir M. M., Keramidas A. D. Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents. Mol. Cell. Biochem. 1995; 153: 17–24
   Google Scholar
• Shechter Y., Ron A. Effect of depletion of phosphate and bicarbonate ions on insulin action in rat adiopcytes. J. Biol. Chem. 1986; 261: 14945–14950
   Google Scholar
• Degani H., Gochin M., Karlish S. J. D., Shechter Y. Electron paramagnetic studies and insulin-like effects of vanadate in rat adipocytes. Biochemistry 1981; 20: 5795–5799
   PubMed Web of Science ®Google Scholar
• Bruck R., Prigozin H., Krepel Z., Rotenberg P., Shechter Y., Bar-Meir S. Vanadate inhibits glucose output from isolated perfused rat liver. Hepatology 1991; 14: 540–544
   Google Scholar
• Miralpeix M., Decaux F. R., Kahn A., Bartrons R. Vanadate induction of L-type pyruvate kinase mRNA in adult rat hepatocytes in primary culture. Diabetes 1991; 40: 462–464
   PubMed Web of Science ®Google Scholar
• Bosch F., Hatzoglou M., Park A. E., Hanson R. W. Vanadate inhibits expression of the gene for phosphoenol-pyruvate carboxykinase in rat hepatoma Cells. J. Biol. Chem. 1990; 265: 13677–13682
   Google Scholar
• Singh J., Nordlie R. C., Jorgenson A. R. Vanadate: a potent inhibitor of multifunctional glucose-6-phosphatase. Biochim. Biophys. Acta 1981; 678: 477–482
   PubMed Web of Science ®Google Scholar
• Clark A. S., Fagan J. M., Mitch W. E. Selectivity of the insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle. Biochem. J. 1985; 232: 273–276
   PubMed Web of Science ®Google Scholar
• D'Onofrio F., Le M. Q., Chiasson J. L., Srivastava A. K. Vanadate dependent activation of mitogen-activated protein (MAP) kinase in Chinese hamster ovary Cells overexpressing a wild type human insulin receptor (CHO-HIRc). Pharmacologist 1993; 35: 109
   Google Scholar
• D'Onofrio F., Le M. Q., Chiassion J. L., Srivastava A. K. Activation of mitogen-activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation. FEBS Lett. 1994; 340: 269–275
   PubMedGoogle Scholar
• Sturgill T. W., Ray L. B., Erikson E., Mailer J. L. Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal S6 kinase II. Nature (London) 1988; 334: 715–718
   PubMed Web of Science ®Google Scholar
• Banerjee P., Ahmad M. F., Grove J. R., Kozlosky C, Price D. J., Avruch J. Molecular structure of a major insu-lin/mitogen-activated 70 kDa S6 protein kinase. Proc. Natl. Acad. Sci. U.S.A. 1990; 87: 8550–8554
   PubMed Web of Science ®Google Scholar
• Pandey S. K., Chiasson J. L., Srivastava A. K. Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases. Mol. Cell. Biochem. 1995; 153: 69–78
   Google Scholar
• Welsh G. I., Foulstone E. J., Young S. W., Tavare J. M., Proud C. G. Wortmannin inhibits the effect of insulin and serum on the activities of glycogen synthase kinases and mitogen-activated protein kinase. Biochem. J. 1994; 303: 15–20
   PubMed Web of Science ®Google Scholar
• Fantus I. G., Kadota S., Deragon G., Foster B., Posner B. I. Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin-receptor tyrosine kinase. Biochemistry 1989; 28: 8864–8871
   PubMed Web of Science ®Google Scholar
• Shisheva A., Shechter Y. Mechanism of pervanadate stimulation and potentiation of insulin-activated glucose transport in rat adipocytes: dissociation from vanadate effect. Endocrinology 1993; 133: 1562–1568
   PubMedGoogle Scholar
• Czech M. P., Lawrence J. C. J., Lynn W. S. Evidence for the involvement of sulfyhydral oxidation in the regulation of fat Cell hexose transport by insulin. Proc. Natl. Acad. Sci. U.S.A. 1974; 71: 4173–4177
   PubMed Web of Science ®Google Scholar
• May J. M., De Haen C. The insulin-like effect of hydrogen peroxide on pathways of lipid synthesis in rat adipocytes. J. Biol. Chem. 1979; 254: 9017–9021
   PubMed Web of Science ®Google Scholar
• Lawrence J.C, Jr, Lamer J. Activation of glycogen synthase in rat adipocytes by insulin and glucose involves increased glucose transport and phos-phorylation. J. Biol. Chem. 1978; 253: 2104–2113
   Google Scholar
• Little S. A., De Haen C. Effects of hydrogen peroxide on basal and hormone-stimulated lipolysis in perfused rat fat Cells in relation to the mechanism of action of insulin. J. Biol. Chem. 1980; 255: 10888–10895
   Google Scholar
• Heffetz D., Zick Y. H2O2 potentiates phosphorylation of novel putative substrates for the insulin-receptor kinase in intact Fao Cells. J. Biol. Chem. 1989; 264: 10126–10132
   PubMed Web of Science ®Google Scholar
• Kadota S., Fantus I. G., Deragon G., Guyda H. J., Hersh B., Posner B. I. Peroxide(s) of vanadium, a novel and potent insulin-mimetic agent which activates the insulin-receptor kinase. Biochem. Biophys. Res. Commun. 1987; 147: 259–266
   PubMedGoogle Scholar
• Posner B. I., Faure R., Burgess J. W., Bevan A. P., Lachance D., Zhang-Sun G., Fantus I. G., Ng J. B., Hall D. A., Lum B. S., Shaver A. Peroxo-vanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J. Biol. Chem. 1994; 269: 4596–4604
   PubMed Web of Science ®Google Scholar
• Yu Z. W., Posner B. I., Smith U., Eriksson J. W. Effects of peroxovanadate and vanadate on insulin binding, degradation and sensitivity in rat adipocytes. Biochim. Biophys. Acta 1996; 1310: 103–109
   Google Scholar
• Li J., Elberg G., Gefel D., Shechter Y. Permolybdate and pertungstate — potent stimulators of insulin effects in rat adipocytes, mechanism of action. Biochemistry 1995; 34: 6216–6225
   Google Scholar
• Swamp G., Cohen S., Garbers D. L. Inhibition of membrane phospho-tyrosyl protein phosphatase activity by vanadate. Biochem, Biophys. Res. Commun. 1982; 107: 1104–1109
   PubMedGoogle Scholar
• Shisheva A., Shechter Y. Quer-cetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry 1992; 31: 8059–8063
   PubMed Web of Science ®Google Scholar
• Mooney R. A., Bordwell K. L., Luhowskyj S., Casnellie J. E. The insulin-like effects of vanadate on lipolysis in rat adipocytes is not accompanied by an insulin-like effect on tyrosine phosphorylation. Endocrinology 1989; 124: 422–429
   PubMed Web of Science ®Google Scholar
• Green A. The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. Biochem. J. 1986; 238: 663–669
   PubMed Web of Science ®Google Scholar
• Shisheva A., Shechter Y. A cytosolic protein tyrosine kinase in rat adiopcytes. FEBS Lett. 1992; 300: 93–96
   Google Scholar
• Shisheva A., Shechter Y. Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. J. Biol. Chem. 1993; 268: 6463–6469
   PubMed Web of Science ®Google Scholar
• Strout H. V., Vicario P. P., Saperstein R., Slater E. E. The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity, nor phosphorylation in mouse diaphragm. in vivo. Endocrinology 1989; 124: 1918–1924
   PubMed Web of Science ®Google Scholar
• Venkatesan N., Davidson M. B. Differential regulation of glucose transport and glucose transporter [GLUT-1] gene expression by vanadate, phorbol ester and okadaic acid in L6 skeletal muscle Cell s. Biochem. Mol. Biol. Int. 1995; 37: 773–783
   Google Scholar
• Shisheva A., Shechter Y. Effect of okadaic acid in rat adipocytes. Differential stimulation of glucose and lipid metabolism and induction of refractoriness to insulin and vanadate. Endocrinology 1991; 129: 2279–2288
   Google Scholar
• Elberg G., Li J., Shechter Y. Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in Cell-free experiments, depending on its oxidation state. J. Biol. Chem. 1994; 269: 9521–9527
   Google Scholar
• Shechter Y., Li J., Meyerovitch J., Gefel D., Bruck R., Elberg G., Miller D. S., Shisheva A. Insulin-like actions of vanadate are mediated in an insulin-receptor-independent manner via non-receptor protein tyrosine kinases and protein phosphotyrosine phosphatases. Mol. Cell. Biochem. 1995; 153: 39–47
   PubMed Web of Science ®Google Scholar
• Liochev S., Fridovich I. The oxidation of NADH by tetravalent vanadium. Arch. Biochem. Biophys. 1987; 255: 274–278
   PubMed Web of Science ®Google Scholar
• Trudel S., Downey G. P., Grinstein S., Paquet M. R. Activation of permeabilized HL60 Cells by vanadate. Evidence for divergent signaling pathways. Biochem. J. 1990; 269: 127–131
   PubMed Web of Science ®Google Scholar
• Grinstein S., Furuya W., Lu D. J., Mills B. G. Vanadate stimulates oxygen consumption and tyrosine phosphorylation in electropermeabilized human neutrophils. J. Biol. Chem. 1990; 265: 318–327
   PubMed Web of Science ®Google Scholar
• Matsubara T., Marcu S. M., Misra P. H., Dhalla N. S. Protective effect of vanadate on oxyradical-induced changes in isolated perfused heart. Mol. Cell. Biochem. 1995; 153: 79–85
   Google Scholar
• Sekar N., Kanthasamy A., William S., Balasubramaniyan N., Govindasamy S. Antioxidant effects of vanadate on experimental diabetic rats. Acta Diabetol. Lat. 1990; 27: 285–293
   PubMedGoogle Scholar
• Younes M., Strubelt O. Vanadate-induced toxicity towards isolated perfused rat livers: the role of lipid peroxi-dation. Toxicology 1991; 66: 63–74
   PubMed Web of Science ®Google Scholar
• Donaldson J., LeBella F. Prooxidant properties of vanadate in vitro on catecholamines and on lipid peroxidation by mouse and rat tissues. J. Toxicol. Environ. Health 1983; 12: 119–126
   PubMed Web of Science ®Google Scholar
• Younes M., Kayser E., Strubelt O. Effect of antioxidants on vanadate induced toxicity toward isolated perfused rat livers. Toxicology 1991; 70: 141–149
   Web of Science ®Google Scholar
• Djordjevic C., Wampler G. L. Antitumor activity and toxicity of peroxo-heteroligand vanadate (V) in relation to biochemistry of vanadium. J. Inorg. Biochem. 1985; 25: 51–55
   PubMed Web of Science ®Google Scholar
• Thompson H. J., Chasteen N. D., Meeker L. D. Dietary vanadyl (IV) sulphate inhibits chemically induced mammary carcinogenesis. Carcinogenesis 1984; 5: 849–851
   PubMed Web of Science ®Google Scholar
• Rijksen G., Voller M. C, Van Zoelen E. J. Orthovanadate both mimics and antagonizes the transforming growth factor beta action on normal rat kidney Cells. J. Cell. Physiol. 1993; 514: 393–401
   Google Scholar
• Cruz F. T., Morgan A., Min W. In vitro and in vivo antineoplastic effects of orthovanadate. Mol. Cell. Biochem. 1995; 153: 161–166
   PubMed Web of Science ®Google Scholar
• Bishayee A., Chatterjee M. Inhibition of altered liver Cell foci and persistent nodule growth by vanadium during diethylnitrosamine induced hepatocarcinogenesis in rats. Anticancer Res. 1995; 15: 455–461
   PubMed Web of Science ®Google Scholar
• Bishayee A., Chatterjee M. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobar-bital. Br. J. Cancer 1995; 71: 1214–1220
   PubMed Web of Science ®Google Scholar
• Klarlund J. K. Transformation of Cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins. Cell 1985; 41: 707–717
   PubMed Web of Science ®Google Scholar
• Marchisio P. C, D'Urso N., Comoglio P. M., Giancotti F. G., Tarone G. Vanadate-treated baby hamster kidney fibroblasts show cytoskeleton and adhesion patterns similar to their Rous Sarcoma virus-transformed counterparts. J. Cell Biochem. 1988; 37: 151–159
   Google Scholar
• Feldman R. A., Lowy D. R., Vass W. C. Selective potentiation of c-fps/ fes transforming activity by a phosphatase inhibitor. Oncogene Res. 1990; 5: 187–197
   PubMedGoogle Scholar
• Kingsnorth A. N., LaMuraglia G. M., Ross J. S., Malt R. A. Vana-date supplements and 1,2-dimethylhydra-zine-induced colon cancer in mice: increased thymidine incorporation without enhanced carcinogenesis. Br. J. Cancer 1987; 53: 683–686
   Google Scholar
• Goldfine A. B., Simonson D. C., Folli F., Patti M-E., Kahn C. R. Metabolic effects of sodium metavanadate in humans with insulin-dependent and non-insulin-dependent diabetes mellitus in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 1995; 80: 3311–3320
   PubMed Web of Science ®Google Scholar
• Cohen N., Halberstam M., Shlimovich P., Chang C. J., Shamoon H., Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1995; 95: 2501–2509
   PubMed Web of Science ®Google Scholar
• Halberstam M., Coehn N., Shlimovich P., Rossetti L., Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese non-diabetic subjects. Diabetes 1996; 45: 659–666
   PubMed Web of Science ®Google Scholar
• Roschin A. V., Ordzhonikide E. K., Shalganova I. V. Vanadium: toxic-ity, metabolism, carrier state. J. Hyg. Epidemol. Microbiol. Immunol. 1980; 24: 377–383
   Google Scholar
• Kawai T., Seiji K., Watanable T., Nakatsuka H., Keda M. Urinary vanadium as a biological indication of exposure to vanadium. Int. Arch. Occup. Environ. Health 1989; 61: 283–287
   PubMed Web of Science ®Google Scholar
• Nechay B. R. Mechanisms of action of vanadium. Annu. Rev. Pharmacol. Toxicol. 1984; 24: 501–524
   PubMed Web of Science ®Google Scholar
• Jandhyala B. S., Horn G. J. Physiological and pharmacological properties of vanadium. Life Sci. 1983; 33: 1325–1340
   PubMed Web of Science ®Google Scholar
• Domingo J. L., Llobet J. M., Tomas J. M., Corbella J. Short-term toxicity studies of vanadium in rats. J. Appl. Toxicol. 1985; 5: 418–421
   PubMed Web of Science ®Google Scholar
• Llobet J. M., Domingo J. L. Acute toxicity of vanadium compounds in rats and mice. Toxicol. Lett. 1984; 23: 227–231
   PubMed Web of Science ®Google Scholar
• Paternain J. L., Domingo J. L., Llobet J. M., Corbella J. Embryotoxic and teratogenic effects of sodium metavanadate administered to rats during orga-nogenesis. Rev. Esp. Fisiol. 1987; 43: 223–228
   PubMedGoogle Scholar
• Shanchez D. J., Ortega A., Domingo J. L., Corbella J. Developmental toxicity evaluation of sodium ortho-vanadate in the mouse. Biol. Trace Elem. Res. 1991; 30: 219–229
   Google Scholar
• Paternain J. L., Domingo J. L., Gomez M., Ortega A., Corbella J. Developmental toxicity of vanadium in mice after oral administration. J. Appl. Toxicol. 1990; 10: 181–186
   PubMed Web of Science ®Google Scholar
• Domingo J. L., Gomez M., Llobet J. M., Corbella J., Keen C. L. Oral vanadium administration to streptozotocin-diabetic rats has marked negative side effects that are independent of the form of vanadium used. Toxicology 1991; 66: 279–287
   PubMed Web of Science ®Google Scholar
• Li J., Elberg G., Shechter Y. Phenylarsine oxide and vanadate: apparent paradox of inhibition of protein phosphotyrosine phosphatases in rat adipocytes. Biochim. Biophys. Acta 1996; 1312: 223–230
   PubMed Web of Science ®Google Scholar